Intrathecal nivolumab 50 mg safe, feasible, and extends survival to 6.6 months in LMD patients
Background
Leptomeningeal metastatic disease (LMD) from solid tumors represents a devastating complication with extremely poor prognosis and high unmet therapeutic need. Systemic immunotherapies, while effective for many advanced cancers, often struggle to penetrate the blood-brain barrier (BBB) sufficiently to treat CNS metastases effectively. This limitation highlights a critical gap in current treatment strategies, driving the exploration of direct central nervous system (CNS) delivery methods for agents like nivolumab, an anti-PD-1 monoclonal antibody, to achieve therapeutic concentrations at the site of disease.
Study Design
This multicenter phase 1 dose-escalation trial (IT-PD1/NOA-26) investigated intraventricular nivolumab in patients with LMD from solid tumors. Participants were eligible if their primary tumor had an approved intravenous PD-1/PD-L1 therapy or high tumor mutational burden. The study enrolled 30 participants, with 24 receiving at least one dose. Four dose levels were tested: 20 mg, 30 mg, 40 mg, and 50 mg of nivolumab administered intraventricularly. The primary endpoint was safety, with an independent data safety monitoring board reviewing each cohort. Overall survival was a secondary endpoint, and participant-reported outcomes were exploratory.
Results
The trial successfully met its primary safety endpoint. Only one dose-limiting toxicity (DLT) was observed, occurring at the 40 mg dose level. Based on these findings, the recommended fixed dose for the ongoing expansion part of the trial is 50 mg of intraventricular nivolumab. Efficacy data showed a median overall survival (OS) of 6.6 months. This represents a significant improvement for a condition typically associated with a median survival of weeks to a few months. The 6-month OS rate was 55.0% (95% confidence interval (CI): 37.5-80.6%), the 12-month OS rate was 33.3% (95% CI: 17.8-62.4%), and the 18-month OS rate was 16.7% (95% CI: 6.03-46.1%). Participant-reported quality of life remained stable throughout the study period, indicating good tolerability beyond just safety metrics.
The establishment of 50 mg as the recommended dose and a median OS of 6.6 months demonstrates the potential of direct CNS immunotherapy for LMD.
Key Findings
- Intraventricular nivolumab demonstrated safety and feasibility in LMD patients.
- Only one dose-limiting toxicity occurred at the 40 mg dose level.
- The recommended fixed dose for expansion is 50 mg intraventricular nivolumab.
- Median overall survival was 6.6 months in this challenging patient population.
- The 6-month OS rate was 55.0%, with 16.7% surviving at 18 months.
Why It Matters
This study provides crucial evidence for the safety and feasibility of directly delivering nivolumab into the CNS for patients with leptomeningeal metastatic disease. Intrathecal nivolumab offers a novel therapeutic strategy for a condition where systemic treatments are largely ineffective due to poor BBB penetration. The identification of 50 mg as the recommended dose is a critical step, enabling further investigation in larger trials. This approach could significantly extend survival and improve quality of life for patients with LMD, a population with extremely limited treatment options. It also paves the way for exploring other immunotherapies via direct CNS routes.
nivolumab
leptomeningeal disease
solid tumors
immunotherapy
pd-1 inhibitor
phase 1 trial